Bioprocessing development is a long and costly process. Building in continuous characterization and connected bioprocessing cuts timelines and increases the available information through real-time analytics.
How an agnostic and data-driven approach early on can optimize the development pathway to bring the molecule to the market faster.
To take advantage of the growing HPAPI market, a company must have the proper controls in place to safely handle these potent compounds and successfully bring its drug to market.
Pediatric drug development requires a formulation designed to fit the specific needs of that patient population. Not considering these requirements early enough could add significant delays.
Before you sign on the dotted line, do a little digging to unearth potential costs that could turn your development program into a cash-burning exercise.
What can you do when the identification method defined by the USP monograph does not provide clear guidance? The authors decided to improve the method with a Quality by Design (QbD) approach.
A platform that combines drug development expertise and biomanufacturing and integrated services to offer advantages to ADC developers.
This webinar explores some use cases to show how machine learning and Big Data analytics can help overcome the challenges facing the biopharmaceutical industry through more confident data-driven decisions.
Striving to bring the way we acquire, share and gain insights from scientific data, through a community and the framework for standardization and linked data.
As compared to IV route, ODT can provide a convenient oral route of administration for proteins, peptides and vaccines. Join experts from Catalent for an overview of the challenges and opportunities in using ODT technology as a patient-centric drug delivery tool and get updates on the new developments in ODT technology including delivery of peptides and vaccines.
With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.
The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties.
Ensure that you always have the exact resources and expertise you need, especially for your most difficult to manufacture compounds.
To be successful, new treatments require superior real world outcomes providing market differentiation and delivering the best outcomes to you, your stakeholders, and most importantly the patients who depend on your therapy.
The challenges, risks and costs of bringing complex large molecule products to market are growing exponentially. Gaining a competitive advantage is more difficult. Drawing on 20 years of biologic experience, Patheon offers you flexible, end-to-end solutions and expertise in development and manufacturing combined with advanced technical capabilities.